Patrick Bingham

Pfizer (United States)

Papers

1

Total Citations

15

H-Index

1

About

Patrick Bingham is a biochemist whose work has advanced the understanding of HIV-1 reverse transcriptase, a critical target in antiretroviral therapy. His research centers on the development of biochemical assays to study viral enzymes, with a particular focus on the ribonuclease H (RNase H) activity of HIV-1 reverse transcriptase—a challenging but promising drug target. Bingham’s most notable contribution is the design and validation of a fluorescence polarization assay for high-throughput screening of RNase H inhibitors, published in 2006. This method provided a sensitive, homogeneous platform for identifying small-molecule inhibitors, addressing a key gap in HIV drug discovery. With 15 citations, the paper remains a foundational reference for researchers exploring RNase H as a therapeutic target. His work has implications not only for HIV treatment but also for broader antiviral strategies, demonstrating how innovative assay design can accelerate drug development. Bingham’s contributions highlight the importance of biochemical tools in translating mechanistic insights into potential therapies, making his research valuable for students and scientists working at the intersection of enzymology and drug discovery.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
A fluorescence polarization assay for screening inhibitors against the ribonuclease H activity of HIV-1 reverse transcriptase
15 citations · 2006
📈 Most Prolific Year: 2006 (1 Papers)
🤝 Key Collaborators: 3
🏛 Institutions: Pfizer (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago